Joanna Seliwiak
About Joanna Seliwiak
Joanna Seliwiak is a Medical Science Liaison in Immunooncology at Bristol-Myers Squibb, with over 19 years of experience in the pharmaceutical industry.
Current Position and Role
Joanna Seliwiak currently serves as a Medical Science Liaison in Immunooncology at Bristol-Myers Squibb. She specializes in facilitating communication between the company and the medical community, ensuring that the latest research and developments in immunooncology are accurately represented and applied. Her role emphasizes fostering relationships with healthcare professionals and key opinion leaders in the field.
Previous Experience at Bristol-Myers Squibb
Joanna Seliwiak has held various positions at Bristol-Myers Squibb over the past 15 years. She served as a Hospital Account Specialist in Hematology, Oncology, and Virology from 2014 to 2016, where she managed accounts and worked closely with hospital staff. Prior to that, she was a Product Specialist from 2008 to 2014, where she gained extensive expertise in pharmaceutical products. These roles have equipped her with comprehensive knowledge in multiple facets of oncology and virology.
Early Career at Roche
Before her tenure at Bristol-Myers Squibb, Joanna Seliwiak worked at Roche as a Medical Representative from 2004 to 2008. In this role, she represented Roche’s medical products to healthcare professionals and worked to foster strong professional relationships within the medical community. Her experience at Roche provided her with a solid foundation in medical representation and product promotion.
Industry Experience and Expertise
Joanna Seliwiak has accumulated over 19 years of experience in the pharmaceutical industry. Her career spans roles in medical representation, product specialization, and medical science liaison. Her extensive background in both product specialization and medical representation has enabled her to understand and effectively communicate complex medical information to a variety of stakeholders. Her expertise is particularly focused on oncology, virology, and immunooncology.